KRISTINA FODOR: Open Payments
NPI 1104395193 · COLORADO SPGS, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,669 in 81 payments from 15 companies in 2025. Trend: 2023 $36 · 2024 $696 · 2025 $1,669
Food & beverage: $1,662Consulting: $7
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $463 |
| Genentech USA, Inc. | 14 | $234 |
| GlaxoSmithKline, LLC. | 17 | $196 |
| Novartis Pharmaceuticals Corporation | 9 | $181 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $154 |
| Amgen Inc. | 6 | $145 |
| GENZYME CORPORATION | 3 | $81 |
| Grifols USA, LLC | 2 | $45 |
| Pharming Healthcare, Inc. | 2 | $45 |
| Ionis Pharmaceuticals, Inc. | 1 | $33 |
Products named: TEZSPIRE, Xolair, FASENRA, NUCALA, DUPIXENT, TRELEGY ELLIPTA, CUVITRU, RUCONEST.
Industry payments across CO — which companies pay providers there.
